Molecular imaging: the emerging role of optical imaging in nuclear medicine

Leeuwen, Fijs W. B. van; Jong, Marion de

doi:10.1007/s00259-014-2845-0

Cited by 18 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was good concordance between SPECT and fluorescence images. While optical agents have limited tissue penetrance due to signal attenuation, they can be useful for complementary intraoperative imaging to ensure that negative surgical resection margins are reached 62 . A phase I study of 111 In-DTPA-G250-IRDye800CW is planned to assess its safety and efficacy in patients (clinical trials.gov, NCT02497599).…”

Section: G250/cg250 For Imagingmentioning

confidence: 99%

Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX

2017

View full text Add to dashboard Cite

Theranostics is the integration of diagnostic information with pharmaceuticals to increase effectiveness and safety of cancer treatments. Nuclear medicine provides a non-invasive means to visualize drug target expression across primary and metastatic sites, and assess pharmacokinetics and efficacy of companion therapeutic agents. This is significant given the increasing recognition of the importance of clonal heterogeneity in treatment response and resistance. Carbonic anhydrase IX (CA-IX) has been advocated as an attractive diagnostic and therapeutic biomarker for targeting hypoxia in solid malignancies. CA-IX confers cancer cell survival under low oxygen tension, and is associated with increased propensity for metastasis. As such, CA-IX is overexpressed in a broad spectrum of cancers. Different classes of antigen recognition molecules targeting CA-IX including monoclonal antibodies, peptides, small molecule inhibitors, and antibody mimetics have been radiolabeled for imaging and therapeutic applications. cG250, a chimeric monoclonal antibody, has been labeled with an assortment of radionuclides (124I, 111In, 89Zr, 131I, 90Y, and 177Lu) and is the most extensively investigated CA-IX radiopharmaceutical. In recent years, there have been tremendous advancements made by the research community in developing alternatives to cG250. Although still in preclinical settings, several small molecule inhibitors and antibody mimetics hold great promise in improving the management of aggressive and resistant cancers.

show abstract

Section: G250/cg250 For Imagingmentioning

confidence: 99%

Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX

2017

View full text Add to dashboard Cite

show abstract

“…However, optical imaging offers interesting applications as well and could complement the nuclear medicine uses (9). An important development in the field of radiopeptides has been the introduction of hybrid derivatives, containing both a fluorescent and a radioactive label, as these have significant implications in the field of imaging-guided surgery.…”

Section: Nuclear/optical Multimodality Imagingmentioning

confidence: 99%

Radiopeptides for Imaging and Therapy: A Radiant Future

2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…These negative features can be partly overcome by using emissions in the near-infrared (NIR) spectrum, but unfortunately optical imaging cannot equal the detailed view and quantitative accuracy that SPECT provides at larger depths. One of the great challenges today is to place these two modalities in perspective and to determine the added value of optical imaging within the field of nuclear medicine [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

U-SPECT-BioFluo: an integrated radionuclide, bioluminescence, and fluorescence imaging platform

et al. 2014

View full text Add to dashboard Cite

BackgroundIn vivo bioluminescence, fluorescence, and single-photon emission computed tomography (SPECT) imaging provide complementary information about biological processes. However, to date these signatures are evaluated separately on individual preclinical systems. In this paper, we introduce a fully integrated bioluminescence-fluorescence-SPECT platform. Next to an optimization in logistics and image fusion, this integration can help improve understanding of the optical imaging (OI) results.MethodsAn OI module was developed for a preclinical SPECT system (U-SPECT, MILabs, Utrecht, the Netherlands). The applicability of the module for bioluminescence and fluorescence imaging was evaluated in both a phantom and in an in vivo setting using mice implanted with a 4 T1-luc + tumor. A combination of a fluorescent dye and radioactive moiety was used to directly relate the optical images of the module to the SPECT findings. Bioluminescence imaging (BLI) was compared to the localization of the fluorescence signal in the tumors.ResultsBoth the phantom and in vivo mouse studies showed that superficial fluorescence signals could be imaged accurately. The SPECT and bioluminescence images could be used to place the fluorescence findings in perspective, e.g. by showing tracer accumulation in non-target organs such as the liver and kidneys (SPECT) and giving a semi-quantitative read-out for tumor spread (bioluminescence).ConclusionsWe developed a fully integrated multimodal platform that provides complementary registered imaging of bioluminescent, fluorescent, and SPECT signatures in a single scanning session with a single dose of anesthesia. In our view, integration of these modalities helps to improve data interpretation of optical findings in relation to radionuclide images.

show abstract

Molecular imaging: the emerging role of optical imaging in nuclear medicine

Cited by 18 publications

References 8 publications

Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX

Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX

Radiopeptides for Imaging and Therapy: A Radiant Future

U-SPECT-BioFluo: an integrated radionuclide, bioluminescence, and fluorescence imaging platform

Contact Info

Product

Resources

About